Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 28;11(10):1022.
doi: 10.3390/life11101022.

Microfluidic Platforms to Unravel Mysteries of Alzheimer's Disease: How Far Have We Come?

Affiliations
Review

Microfluidic Platforms to Unravel Mysteries of Alzheimer's Disease: How Far Have We Come?

Pragya Prasanna et al. Life (Basel). .

Abstract

Alzheimer's disease (AD) is a significant health concern with enormous social and economic impact globally. The gradual deterioration of cognitive functions and irreversible neuronal losses are primary features of the disease. Even after decades of research, most therapeutic options are merely symptomatic, and drugs in clinical practice present numerous side effects. Lack of effective diagnostic techniques prevents the early prognosis of disease, resulting in a gradual deterioration in the quality of life. Furthermore, the mechanism of cognitive impairment and AD pathophysiology is poorly understood. Microfluidics exploits different microscale properties of fluids to mimic environments on microfluidic chip-like devices. These miniature multichambered devices can be used to grow cells and 3D tissues in vitro, analyze cell-to-cell communication, decipher the roles of neural cells such as microglia, and gain insights into AD pathophysiology. This review focuses on the applications and impact of microfluidics on AD research. We discuss the technical challenges and possible solutions provided by this new cutting-edge technique to understand disease-associated pathways and mechanisms.

Keywords: 3D culture; Alzheimer’s disease; lab-on-chip; microfluidics; organ-on-chip.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
The pathophysiology of Alzheimer’s disease is very complex. Major pathological hallmarks of Alzheimer’s disease are provided. Among all the hallmarks, Aβ accumulation is considered the major cause of neurodegeneration in Alzheimer’s disease. It has been found that all other causes such as tau pathology and/or neuroinflammation ultimately converge to Aβ accumulation. For instance, microglia, the innate immune system of the nervous system, mediates neuroinflammation by the production of cytokines such as IL33, IL-8 and IL-1β. Microglial activation initiates inflammation of the neural tissues. The cytokines (IL-33) produced in the due process help in Aβ clearance whereas IL-8 and IL-1β cause synaptic dysfunction. This molecular mechanism reflects the complex.
Figure 2
Figure 2
Timeline of the progress of microfluidics in biomedical research. Abbreviations: GC, gas chromatography; µTAS, micro total analysis system; PDMS, Polydimethylsiloxane.
Figure 3
Figure 3
Schematic representation of the materials used for the fabrication of microfluidic chips. Hydrogels made up of natural materials, i.e., alginate, serve as matrices for culturing of cells in microfluidic chips. Thermoplastics such as polyvinyl chloride, polystyrene and high-density polyethylene are commonly used in fabrication. Moreover, the typical white color of paper makes it well suited for color-based detection methods in most assays and used for multiple bioassays in the form of origami-inspired folding devices. Elastomer is generally made up of PDMS. The glass-based microfluidic channel is made by the laser direct writing method. Thermoset, polyester-based, is a droplet-based device that can be used at different flow rates with three different oils.

References

    1. Jha N.K., Jha S.K., Kar R., Nand P., Swati K., Goswami V.K. Nuclear factor-kappa β as a therapeutic target for Alzheimer’s disease. J. Neurochem. 2019;150:113–137. doi: 10.1111/jnc.14687. - DOI - PubMed
    1. Crimins J.L., Pooler A., Polydoro M., Luebke J.I., Spires-Jones T.L. The Intersection of Amyloid Beta and Tau in Glutamatergic Synaptic Dysfunction and Collapse in Alzheimer’s Disease. Ageing Res. Rev. 2013;12:757–763. doi: 10.1016/j.arr.2013.03.002. - DOI - PMC - PubMed
    1. Kumar P., Jha N.K., Jha S.K., Ramani K., Ambasta R.K. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: Clinical relevance in Alzheimer’s disease. J. Alzheimers Dis. 2015;43:341–461. doi: 10.3233/JAD-140933. - DOI - PubMed
    1. Lee J.C., Kim S.J., Hong S., Kim Y.S. Diagnosis of Alzheimer’s Disease Utilizing Amyloid and Tau as Fluid Biomarkers. Exp. Mol. Med. 2019;51:1–10. doi: 10.1038/s12276-019-0250-2. - DOI - PMC - PubMed
    1. Jha S.K., Jha N.K., Kumar D., Sharma R., Shrivastava A., Ambasta R.K., Kumar P. Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer’s Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets? J. Alzheimers Dis. 2017;57:1017–1039. doi: 10.3233/JAD-160623. - DOI - PubMed

LinkOut - more resources